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Abstract 
A major domain of depression is amotivation for reward. Translational automated tests can be 
applied in humans and animals to study operant reward behaviour, aetio-pathophysiology underlying 
deficits therein, and effects of antidepressant treatment. Three inter-related experiments were 
conducted to investigate depression-relevant effects of chronic psychosocial stress on operant 
behaviour in mice. (A) Non-manipulated mice were trained on a complex reversal learning (CRL) test 
with sucrose reinforcement; relative to vehicle (VEH), acute antidepressant agomelatine (AGO, 25 
mg/kg p.o.) increased reversals. (B) Mice underwent chronic social defeat (CSD) or control handling 
(CON) on days 1-15, and were administered AGO or VEH on days 10-22. In a progressive ratio 
schedule motivation test for sucrose on day 15, CSD mice made fewer responses; AGO tended to 
reverse this effect. In a CRL test on day 22, CSD mice completed fewer reversals; AGO tended to 
increase reversals in CSD mice associated with an adaptive increase in perseveration. (C) Mice with 
continuous operant access to water and saccharin solution in the home cage were exposed to CSD or 
CON; CSD mice made fewer responses for saccharin and water and drank less saccharin in the active 
period, and drank more water in the inactive period. In a separate CSD cohort, repeated AGO was 
without effect on these home cage operant and consummatory changes. Overall, this study 
demonstrates a mouse model of amotivation in the form of psychosocial stress-induced deficits in 
operant reward behaviour; partial reversal of these deficits by AGO provides evidence for predictive 
validity. 
 
Keywords: depression; amotivation; animal model; operant; circadian rhythm; agomelatine  
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1. Introduction 
Depression is a major and heterogeneous neuropsychiatric disorder. Core psychopathological 
symptoms are depressed mood, diminished interest in activities, and increased fatigue, together with 
a number of common symptoms including weight loss or gain, psychomotor agitation or retardation, 
insomnia or hypersomnia, and reduced concentration and attention (DSM-5, 2013; ICD-10, 1994). 
The recent Research Domain Criteria (RDoC) project (Cuthbert, 2015; Cuthbert and Insel, 2013) 
proposes a classification system that takes diagnostic systems into account but also identifies the 
importance of understanding individual psychopathologies, which have been organised into 
domains: for example, the Positive valence systems domain, which includes approach motivation, 
responsiveness to reward and reward learning; and the Arousal/modulatory systems domain which 
includes arousal, biological rhythms and sleep-wake (Cuthbert and Insel, 2013). Integrating RDoC 
with depression symptomatology, the Positive valence systems domain is clearly relevant to 
diminished interest and the Arousal/modulatory systems domain is clearly relevant to insomnia or 
hypersomnia. Depression is not well-understood in terms of aetio-pathophysiology, and patients 
with different symptom combinations are also likely to differ at the pathophysiological level. The 
RDoC approach is conducive with translational research aimed at increasing understanding of 
disorder pathophysiology. This includes evidence obtained from animal models that combine 
manipulations with aetiological validity with behavioural readout tests with face validity for specific 
psychopathologies (Pryce and Seifritz, 2011).  
 Chronic psychosocial stressors are major aetiological risk factors for depression (Kendler et 
al., 2003; Kessler, 1997). In mice, one form of environmental manipulation proposed to model 
aspects of human psychosocial stress is chronic social defeat (CSD). It comprises 10-15 days of 
continuous intruder status in the home cages of different dominant mice but protected by a divider, 
with brief daily experience of actual physical attack and defeat (Golden et al., 2011; Kudryavtseva et 
al., 1991). We and others could demonstrate that CSD leads to increased sensitivity to and impaired 
coping with aversive stimuli (e.g. (Azzinnari et al., 2014). Furthermore, CSD has been reported to 
result in decreased preference for gustatory reward, namely sweet-tasting sucrose solution, over 
water in the two-bottle test of consummatory behaviour (Krishnan et al., 2007). Somewhat in 
contrast, in human depression, patients do not exhibit reduced subjective pleasure when given a 
rewarding stimulus (Dichter et al., 2010). However, when required to exhibit high effort to obtain 
reward, depressed patients are less motivated to do so (Sherdell et al., 2012). This evidence that, in 
depression, positive-valence processing is reduced at the motivational level rather than the 
consummatory level, highlights the need for animal models of stress-induced impairment of reward 
motivation and anticipation. These processes can be best-studied using behaviour-outcome 
(operant) tests.  
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 In order to investigate reward motivation per se, a single operant stimulus can be used with 
reinforcement earned according to a specific schedule. In animal studies, the reinforcer typically 
takes the form of palatable food. The progressive ratio schedule (PRS) test requires the subject to 
make an increasing number of responses to obtain successive rewards and is therefore sensitive to 
assessing the motivation for effortful responding for reward. By conducting the PRS test with the 
animal subject close to hunger satiety, the anticipated palatability of the sucrose-pellet reward 
becomes more important relative to its calorific value, thereby increasing the test’s sensitivity for 
assessing reward motivation. For example, in adult rats it has been demonstrated that early life 
stress leads to decreased responding for reward in a PRS test (Leventopoulos et al., 2009). Using 
tests comprising two operant stimuli that need to be discriminated between in order to obtain 
reinforcement, then a number of further depression-relevant reward processes can be investigated. 
When depressed patients are assessed in discrimination tests that require low effort to obtain 
reward, typically either symbolic (emoticon e.g. smiling face) or monetary, they do not differ from 
healthy subjects in terms of accuracy of responding (Taylor Tavares et al., 2008). However, their 
responding is characterised by high sensitivity to error feedback: when depressed patients make an 
error and therefore fail to receive reinforcement on a trial, they are more likely to make an incorrect 
decision on the subsequent trial (Elliott et al., 1996; Elliott et al., 1997). The probabilistic reversal 
learning (PRL) test assesses reward-directed decision making under conditions of accurate and 
misleading reinforcement/feedback (Chamberlain et al., 2006; Cools et al., 2002; Evers et al., 2005; 
Jocham et al., 2009). The test comprises reversal learning, which requires responding to regular shifts 
in the contingencies - reward, non-reward - between the two operant stimuli and reinforcement and, 
superimposed on this, at a certain probability correct responses are not rewarded whereas incorrect 
responses are rewarded. The proportion of non-rewarded correct responses on which the subject 
shifts (to the incorrect stimulus) on the next trial, gives a measure of negative feedback sensitivity 
(NFS). High NFS is indicative of under-estimation of reward probability and is increased in depressed 
patients (Taylor Tavares et al., 2008). Recently, rodent automated operant PRL tests have been 
developed, firstly for rat (Bari et al., 2010) and then in our laboratory for mouse (Ineichen et al., 
2012). In order to ensure that motivation for sucrose-pellet reinforcement is sufficient for rodents to 
engage in this demanding test, some food deprivation is essential. In the mouse PRL test, given that 
misleading feedback is restricted to non-rewarded correct responses (without any rewarding of 
incorrect responses), we refer to it here as a complex reversal learning (CRL) test. Non-manipulated 
mice exhibit: (1) reward-stay behaviour consistent with accurate monitoring of the average reward 
probability at each stimulus; (2) low perseveration and high NFS consistent with accurate monitoring 
of expected and unexpected non-reward; (3) reduced reversals achieved relative to performance in a 
simple reversal learning test without any non-rewarded correct responses (Ineichen et al., 2012).  
5 
 
 Agomelatine (AGO; S 20098) is an agonist at melatonergic (MT1/MT2) receptors and an 
antagonist at serotoninergic 2C (5-HT2C) receptors, and was recently approved in Europe for the 
treatment of major depression (de Bodinat et al., 2010; Kennedy et al., 2014). During its preclinical 
development, using repeated dosing, AGO was shown to be efficacious in several rat and mouse 
models relevant to depression domains (de Bodinat et al., 2010). These include reversal of decreased 
saccharin consumption induced by chronic mild stress (Papp et al., 2003), reversal of specific learned 
helplessness (Bertaina-Anglade et al., 2006), antagonism of increased anxiety and decreased 
grooming induced by repeated corticosterone administration (Rainer et al., 2012), and antagonism of 
increased anxiety, immobility in the forced swim test, and altered circadian rhythm of activity and 
sleep-wake pattern induced by prenatal restraint stress (Mairesse et al., 2013; Marrocco et al., 2014; 
Morley-Fletcher et al., 2011). In clinical trials, therapeutic efficacy of AGO is increased relative to 
placebo in moderate to severe depression (Kennedy et al., 2014). When the core symptom/domain 
of interest-pleasure was measured using a self-report questionnaire, in depressed patients efficacy of 
AGO on anhedonia was increased relative to venlafaxine (Di Giannantonio and Martinotti, 2012; 
Martinotti et al., 2012). In terms of operant tests of reward processing, whilst there are no published 
studies with AGO to-date, a 5-HT2C antagonist compound was demonstrated to improve reversal 
learning, in part by decreasing perseveration, in a rat model (Boulougouris et al., 2008). 
 The overall aim of the present study was to establish a mouse model of psychosocial stress-
induced impaired reward processing and to investigate its predictive validity with the antidepressant 
AGO. Three inter-related experiments were conducted: (1) Investigation of the effects of acute 
administration of AGO, melatonin and a 5-HT2C antagonist on behaviour of control mice in the 
complex reversal learning test, to establish an effective AGO dose and its mechanism of action. (2) 
Investigation of the effects of 15-day CSD (Azzinnari et al., 2014) on operant behaviour in a 
progressive ratio schedule test and in simple and complex reversal learning tests, and of the effects 
of repeated AGO administration on CSD-induced deficits. (3) Investigation of the effects of 15-day 
CSD on the amount and circadian distribution of operant responding for saccharin solution versus 
water in a home cage setting, and of the effects of repeated AGO administration on CSD-induced 
deficits.   
 
2. Experimental procedures 
2.1. Animals 
Experiments were conducted with adult male C57BL/6J (BL/6J) mice bred in house, maintained in 
littermate pairs, and aged 10 weeks and weighing 26-28 g at study onset. Male CD-1 mice (Janvier, Le 
Genest-Saint-Isle, France) used for social stress were aged 8 months, weighed 40-45 g, were ex-
breeders, and caged singly. Mice were maintained on a reversed light-dark cycle (light off 07:00-
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19:00 h). Standard home cages were type 2L and maintained in an individually-ventilated caging 
system. One study was conducted using IntelliCages (see below). Both cage types contained sawdust, 
tissue bedding and a sleep igloo. Temperature was maintained at 22°C and humidity at 50-60%. The 
standard diet was Complete Pellet (Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water, both 
available continuously unless otherwise stated below. BL/6J mice were handled on 5 days at study 
onset. The studies were conducted under a permit (170/2012) for animal experimentation issued by 
the Veterinary Office, Zurich, Switzerland. All efforts were made to minimize the number of mice 
studied and any unnecessary stress to those mice that were studied. 
 
2.2. Experimental design 
Three studies (A, B, C) were conducted, each with a different cohort of naive mice (Figure 1). The first 
stage of each study was operant training for reinforcement with sucrose-pellet (A, B) or saccharin-
solution and water (C). In Study A (N=24), we investigated the effects of acute agomelatine (AGO), 
melatonin and S32006, a 5-HT2C receptor antagonist, on behaviour in a complex reversal learning 
(CRL) test in otherwise non-manipulated mice. In Study B (N=44), we investigated the effects of 
chronic social defeat (CSD, days 1-15, versus control handling (CON)) and AGO (days 10-22, versus 
vehicle (VEH)) on behaviour in a progressive ratio schedule (PRS) test (day 8 and day 15), a simple 
reversal learning (SRL) test (day 19) and the CRL test (day 22). Study C comprised two experiments in 
IntelliCage: Firstly, we investigated the effects of CSD (days 1-15, versus CON) (N=20) on appetitive 
and consummatory behaviour towards water and saccharin solution during the dark- and light-
phases of the circadian cycle. Second, in a new cohort (N=16) the effects of AGO (days 7-20, versus 
VEH) on these same measures were studied in CSD mice (days 1-15).  With respect to the timeline of 
behavioural tests, in Study B, the two PRS tests allowed for assessment of development of CSD 
effects on reward motivation; this test is conducted in the absence of food deprivation and therefore 
no food deprivation was necessary during CSD (see below). The SRL and CRL tests allowed for 
assessment of post-CSD effects on these respective reversal learning challenges; food deprivation is 
required for these tests and this was an important factor in conducting these tests after completion 
of CSD. With respect to the timeline of agomelatine administration, in Studies B and C the aim was to 
initiate agomelatine administration at the mid-point of CSD (day 10 in Study B to allow for pre-drug 
testing of CSD effects in the progressive ratio schedule test on day 8) so that its effects on reversal - 
rather than prevention - of CSD effects could be investigated. The duration of agomelatine 
administration of 13-14 days was informed by previous studies demonstrating reversal of stress-
induced behavioural effects after 2 weeks of agomelatine administration e.g. recovery of sucrose 
drinking in rats exposed to chronic mild stress (Papp et al., 2003). 
     FIGURE 1 ABOUT HERE 
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2.3. Chronic social defeat 
Our refined protocol for chronic social defeat is described in detail elsewhere (Azzinnari et al., 2014). 
As in the majority of CSD protocols, the strain used as the stressor was CD-1. Ex-breeder males of this 
strain attack with a short latency and are generally larger than BL/6 males, thereby allowing for 
reliability in terms of the direction of the dominant-subordinate relationship. Also, CD-1 mice 
continue to attack when BL/6 mice display submissive behaviours, such that the latter experience 
lack of social control. In Study B, each BL/6J (CSD) mouse was placed singly in the 2L home cage of a 
CD-1 mouse, separated by a transparent, perforated divider. The CSD mouse was placed in the same 
compartment as the CD-1 mouse for either a cumulative total of 60-s physical attack (chase, wrestle, 
bite) or 10 min maximum. To prevent bite wounds, the lower incisors of CD-1 mice were trimmed 
every third day across CSD. The CSD mouse x CD-1 mouse pairings were rotated so that CSD mice 
were placed in the home cage of and confronted with a novel CD-1 mouse each day. This CSD 
procedure was conducted for 15 days, between 14:00-16:00 h. From day 16 until the end of operant 
testing, each CSD mouse remained in one cage with the same CD-1 mouse, without further attacks. 
The rationale for this was that following 15 proximate exposures to CD-1 mice, distal exposure to 
such a mouse should continue to represent a stressor until the end of the experiment. Control (CON) 
mice remained in littermate pairs, the standard condition in our laboratory, and were handled and 
weighed daily. For details of the CSD procedure in Study C, see sub-section IntelliCage appetitive and 
consummatory behaviour.  
 
2.4. CSD effects on feeding homeostasis and appetite hormones 
Given that the reversal-learning operant tests require food deprivation (Ineichen et al., 2012), and 
that CSD is known to increase food intake and alter blood levels of appetite-regulating hormones in a 
pro-feeding direction (Kumar et al., 2013; Patterson et al., 2013), for Study B it was necessary to 
establish the effects of our CSD protocol on home-cage food intake and appetite hormone levels. In a 
separate experiment with naive mice, daily intake of food pellet was measured in 11 littermate pairs 
for 5 days prior to allocation to CSD (N=12) and CON (N=10) and measurement of daily intake of food 
pellet across the 15 days. For mice in pairs, pellet consumption per mouse was estimated by dividing 
the total amount of pellet eaten by two and adjusting for respective body weights. On day 16, mice 
were decapitated and trunk blood collected into 500 µl tubes coated with EDTA (Microvette, 
Sarstedt), and 4-2-aminoethyl-benzenesulfonyl fluoride (Sigma) was added at 1 mg/ml. The blood 
was centrifuged at 3000 rpm for 15 min at 4°C, the plasma was removed to Eppendorf Protein LoBind 
tubes, and acidified with hydrochloric acid to a final concentration of 0.05 N. Plasma samples were 
stored at -20°C until determination of leptin and acylated ghrelin using ELISA kits according to the 
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manufacturer’s protocol (Mouse Leptin EZML-82K, Rat/Mouse Ghrelin (active) EZRGRA-90K, Merck 
Millipore).         
 
2.5. Operant training and testing  
Controlled feeding and body weight. In Studies A and B, body weight (BW) and food intake of BL/6J 
mice were measured every day for one week and the mean values were calculated and taken as 
baseline for each mouse. To ensure that mice were motivated for operant training, BW was reduced 
to 90-95% baseline by controlling daily pellet allowance. In Study B, at 5 days prior to and throughout 
CSD, mice were given sufficient daily pellet to return to and maintain 100% baseline BW. They were 
then maintained at baseline BW for progressive ratio schedule testing and reduced to 95% baseline 
BW for reversal learning tests. 
    
Operant chambers. Modular operant chambers (TSE Systems, Bad Homburg, Germany, (Ineichen et 
al., 2012)) were used for Studies A and B. Briefly, each chamber contained one (progressive ratio 
schedule test) or two (reversal learning tests) operant nose-poke apertures and one feeder that 
delivered one sucrose pellet per reinforcement (14 mg Dustless Precision Pellets, TSE Systems). 
Correct and incorrect nose-pokes and pellet retrieval were detected via infrared beam breaks in the 
respective apertures. A loudspeaker above the feeder emitted a tone to signal reward delivery. After 
each session the chambers were cleaned with 70% ethanol.    
  
Training on fixed-ratio 1 (FR1) operant reinforcement. In Studies A and B, mice were conditioned to 
nose poke on a fixed-ratio 1 (FR1) schedule for sucrose pellet reinforcement during five sessions per 
week for 1-2 weeks, using the training stages detailed in (Ineichen et al., 2012). The basic settings 
were: trial onset was indicated by illumination of the nose-poke aperture(s); one response (FR1) 
initiated tone and pellet delivery, and following pellet retrieval a 2.5 s inter-trial interval (ITI) was 
initiated; the session terminated after 40 reinforcements or 30 min. 
 
Progressive ratio schedule (PRS) test. The PRS test was used in Study B, and conducted as described 
elsewhere (Ineichen et al., 2012; Bergamini et al., in press). Briefly, only one nose-poke aperture was 
used. The maximum session duration was 40 min. Session parameters were: required number of 
responses on first trial = 1, number of consecutive trials for which the ratio remained constant = 5, 
and number of responses by which the ratio increased per increment = 3, i.e. on trials 1-5, 1 response 
was required, on trials 6-10, 4 responses, on trials 11-15, 7 responses, and so on. If there was no 
single response within any 600-s period the break point was reached and the session terminated. 
Measures were total number of nosepokes, number of reinforcements attained, final ratio attained, 
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and total number of responses at the feeder. In Study B, at 100% baseline BW, mice were given two 
PRS tests on consecutive days, and the scores on the second day were used to counter-balance 
allocation of mice to CSD and CON groups in terms of reward motivation (Fig. 1B). Mice were tested 
at 100% baseline BW for CSD effects in the PRS test at CSD days 8 and 15, with testing conducted, 
before the daily CSD session, at 09:00-12:00 h. Within CSD and CON mice, PRS behaviour at CSD day 
8 was used to counter-balance allocation of mice to AGO and VEH drug groups.   
 
Simple reversal learning (SRL) test. In Studies A and B, mice were trained on reversal learning, using 
two nose-poke apertures positioned left and right of the central feeder. The final parameters for 
reversal training, and also the parameters used in the SRL test itself, were: On FR1, a response at the 
correct aperture initiated tone and pellet delivery followed by 2.5 s ITI, and a response at the 
incorrect aperture initiated 5-s time out. Consistent reward-stay behaviour in the form of eight 
consecutive correct responses/reinforcements was required for reversal. At reversal the previously 
incorrect aperture was now correct and vice versa, so that nonreward-shift behaviour was required. 
The total number of pellets available was 48, giving a maximum of six reversals. Criteria for 
completion of reversal-test training were all 48 reinforcements obtained and consumed, a minimum 
of 18 (p≥0.75) reward-stay responses per aperture, and a minimum of 3 reversals completed. Mice 
required 35-40 sessions, 5 days per week, from onset of operant training to reach these criteria for 
reversal learning. The final settings described above were also the settings for the actual SRL test. 
The measures of interest were as described below for the complex reversal test, except there was no 
measure, negative feedback sensitivity.        
     
Complex reversal learning (CRL) test. The CRL test was used in Studies A and B, and was conducted 
as reported elsewhere (Ineichen et al., 2012) where the same test was described as probabilistic 
reversal learning. (Given that in “real” probabilistic reversal learning tests both a proportion of 
correct responses are not rewarded and a proportion of incorrect responses are rewarded (e.g. Bari 
et al. (2010), whereas in the present test only the former contingency was used, we use the term 
complex reversal learning test.) Briefly, the same parameters as in the SRL test were used with the 
addition of an overall probability of 0.15 that responses to the correct aperture were not rewarded; 
these were called non-rewarded correct responses (NR-CRs). The first correct response per session 
was always rewarded and the maximum number of consecutive NR-CRs was 2. A maximum of 60 
pellets could be obtained and the maximum amount of reversals was 7 therefore. Measures of 
interest were: Reward-stay probability, calculated as p (trials with response to the aperture that was 
correct on previous trial/total trials immediately following a correct trial). Number of reversals 
completed. Perseverations/reversal, immediately following reversal, the number of consecutive trials 
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required to switch to the new correct aperture /total reversal completed. Trials/reversal, mean 
number of trials required to complete a reversal. Negative feedback sensitivity, calculated as p (trials 
with response to the opposite aperture following a NR-CR/total trials immediately following a NR-
CR). Average latency to collect reward, mean time (ms) required to collect the pellet from the feeder. 
Session duration, the time (s) needed to finish the session by obtaining 60 pellets or 1800 s 
maximum.  
 In Study A, all mice were given five CRL tests, each preceded by a different compound (see 
section Drugs below). Mice were given the SRL test on days between CRL tests, to ensure that they 
were exhibiting normal baseline performance on the day prior to compound-CRL testing (Fig. 1).   
 In Study B, following CSD (day 15) mice were returned to food restriction on day 16 to reduce 
BW to 95% baseline. They were given a SRL test on day 19, and a CRL test on day 22; these were days 
10 and 13 of daily AGO/VEH administration, respectively (Fig. 1, section Drugs below).  
  
IntelliCage appetitive and consummatory behaviour. In Study C (Fig. 1C), IntelliCage (TSE) was used, 
a system for automated continuous monitoring of appetitive and consummatory behaviour of mice 
in their home cage, as described elsewhere (Cathomas et al., 2015a; Cathomas et al., 2015b). Briefly, 
each IntelliCage was divided at the centre by a transparent, perforated divider to give two 
independent compartments, and placed in an attenuation chamber with a 12:12 h reversed light-
dark cycle (light off 07:00-19:00 h). Mice were fitted with a subcutaneous transponder to record: 
visits to the operant devices located in each corner; operant nosepokes into a light sensor aperture 
at the door in each corner that opened on FR1 to allow access to a drinking bottle; and the number 
of licks, measured by electrical contact of the tongue with the drinking tip. Littermate pairs were 
habituated to the cage for 3 days with operant doors open, and then the doors were closed so that 
mice had to nosepoke to open a door and access the water bottle for 20 s, for a training period of 7 
days. This was followed by 5 days of training with one water bottle and one saccharin solution (0.1%, 
sodium salt hydrate, Sigma) bottle, the corner locations of which were alternated each day at 17:00 
h. For 10-day baseline data collection, the littermate pair was separated with one mouse placed in 
each compartment, and they were exchanged between compartments each day at 17:00 h. In the 
first experiment (Fig. 1C1), this continued for a further 15 days in the case of CON mice. In CSD mice, 
one littermate was removed and replaced by a CD-1 mouse. The CSD procedure was conducted at 
16:00-17.00 h for 15 days. Thus CSD immediately preceded the time of exchanging compartments 
and bottle locations during baseline data collection: the CSD mouse was placed in the compartment 
occupied by the CD-1 mouse for either a cumulative total of 60-s physical attack or 10 min maximum, 
and then the CSD mouse remained in this compartment and the CD-1 mouse was transferred to the 
opposite compartment. CD-1 mice were provided with a normal water bottle; they were rotated 
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between IntelliCages every fifth day and lower incisors were trimmed every third day. In the second 
experiment (Fig. 1C2), after the 10-day baseline data collection, the CSD procedure was conducted 
on days 1-15. On days 16-20, the CSD and CD-1 mice were exchanged between compartments at 
16:00 h without further attacks. As in Study B, the rationale for this was that after 15 proximate 
exposures to CD-1 mice, distal exposure to such a mouse would continue to represent a stressor until 
the end of the experiment. AGO/VEH were administered at days 7-20, at 06:00-06:30 (see section 
2.6). For statistical analysis, four time blocks of interest were identified: two during the light phase, 
20:01-00:00, 00:01-04:00, and two during the dark phase, 08:01-12:00, 12:01-16:00. Therefore, the 
data collected during the 3-4 hours directly after CSD/CON and compartment transfer were not 
included in the statistical analysis, as was also the case for the data collected during the 2 hours after 
AGO/VEH administration. This was done to avoid inclusion of any acute effects of CSD, compartment 
transfer or compound administration in the data set, with the focus being on analysing for sustained 
effects of CSD and AGO, and during both the dark phase and light phase. 
 
2.6. Drugs 
To establish dose and time effects on AGO levels, naive mice (N=6-7 per dose x time point) were 
orally (p.o.) administered 10 or 25 mg/kg AGO using intragastric gavage, and trunk blood and brain 
were collected after 1 h or 3 h and stored at -80°C prior to analysis. AGO measurement in plasma and 
brain-tissue homogenate was performed according to an established method involving liquid-liquid 
extraction of a sample volume of 20 µl, and liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) detection. S 40706-1 (D5-20098) was used as an internal standard. The 
limit of quantification (LLOQ) was 0.100 ng/mL (range 0.100 to 30 ng/mL). All LC-MS/MS 
measurements were performed by a central analytical laboratory.  
 All compounds were prepared fresh in a vehicle of 1% hydroxyethylcellulose (HEC) in water. 
In Study A, acute AGO was studied at 10 and 25 mg/kg p.o., acute melatonin (MT) at 10 mg/kg p.o., 
and the 5-HT2C antagonist S 32006 acutely at 2.5 mg/kg p.o. The melatonin dose of 10 mg/kg was 
based on previous demonstrations of efficacy of this dose in preventing stress-induced behavioural 
effects in mice (e.g. Gumuslu et al., 2014). The S 32006 dose of 2.5 mg/kg was based on pilot study 
evidence that 5 and 10 mg/kg increased session duration in reversal tests suggesting inhibition of 
responding. A latin square design was used to test compound effects in a counterbalanced order 
across mice. A period of 3-4 days was allowed between each day of compound-CRL testing (Fig. 1A). 
In Study B, 13-day repeated AGO was studied at 25 mg/kg p.o.. In Study C, 14-day repeated AGO was 
studied at 25 mg/kg p.o.. Compounds were administered at the end of the light phase (06:00-06:30 
h) in all studies; 1-2 hours prior to operant testing in Studies A and B, and 2 hours prior to onset of 
collection of data used in the statistical analysis in Study C.    
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2.7. Statistical analysis 
Statistical analysis was conducted using SPSS (version 21, SPSS Inc., Chicago IL, USA). In Study A, drug 
effects on dependent measures in the CRL test were analysed using repeated measures analysis of 
variance (ANOVA). In Study B, CSD effects on food required to maintain baseline BW at specific time 
points were studied using t-tests. 2 Stress (CSD, CON) x 2 Drug (AGO, VEH) full-factorial ANOVA was 
used to study effects on behavioural measures in the PRS, SRL and CRL tests. In Study C, in the first 
experiment 2 Stress (CSD, CON) x 4 Day-block (Baseline, CSD/CON 1-5, 6-10, 11-15) x 4 Time-block 
(20-00 h, 00-04 h, 08-12 h, 12-16 h) mixed-factorial ANOVA was used to study effects on IntelliCage 
measures; and in the second experiment 2 Drug (AGO, VEH) x 5 Day-block (Baseline, CSD 1-5, CSD-
Drug 6-10, CSD-Drug 11-15, Drug 16-20) x 4 Time-block (20-00 h, 00-04 h, 08-12 h, 12-16 h) ANOVA 
was used to study effects on IntelliCage measures. Significant main or interaction effects were 
analysed using post hoc testing with Bonferroni correction for multiple comparisons. Significance was 
set at p≤0.05 and a non-significant trend at 0.05<p<0.10. Effect size values were calculated as 
Cohen’s d for t-test and partial eta squared (2) for ANOVA. Data are given as means and where an 
estimate of variance is given this is the standard deviation (SD). 
 
3. Results 
3.1. Agomelatine pharmacokinetics 
In naive mice, agomelatine blood and brain levels following p.o. administration at 10 or 25 mg/kg and 
sample collection after 1 or 3 h are given in Figure 2. In plasma there was a Dose x Time interaction 
effect on AGO levels (F(1, 20)=9.52, p<0.006, partial 2=0.32, Fig. 2A) and the same was the case for 
whole brain levels (F(1, 22)=4.34, p<0.05, partial 2=0.17, Fig. 2B). In each compartment, AGO levels 
were increased at 1 h after administration of 25 mg/kg p.o. relative to all other Dose x Time points, at 
which AGO levels were detectable and low.  
 
     FIGURE 2 ABOUT HERE 
 
3.2. Study A: Effects of acute agomelatine in the complex reversal learning test 
In naive mice in the CRL test, each mouse was tested following acute p.o. AGO at 10 mg/kg (AGO 10) 
or 25 mg/kg (AGO 25), melatonin (MT) at 10 mg/kg, and S 32006  (5-HT2C ANT) at 2.5 mg/kg, using a 
latin square design. As given in Figure 3, there was no Drug effect on reward-stay behaviour (p=0.30, 
Fig. 3A), and also no Drug effect on negative feedback sensitivity (p=0.40, Fig. 3B). For number of 
reversals completed, there was a main effect of Drug (F(4, 114)=3.06, p<0.05, partial 2=0.11, Fig. 
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3C); post hoc testing demonstrated that, relative to VEH, mice completed more reversals after AGO 
25 (p<0.05) and 5-HT2C ANT (p<0.03).     
 Based on both the pharmacokinetic and CRL test data, 25 mg/kg AGO was the dose selected 
for repeated oral administration in Studies B and C. 
     FIGURE 3 ABOUT HERE 
 
3.3. Study B: Effects of CSD and repeated agomelatine on reward motivation and response 
accuracy in discrete operant tests 
CSD effects on feeding homeostasis and appetite hormones 
Prior to Study B, in a separate cohort of naive mice we investigated CSD effects on food intake under 
ad libitum conditions and plasma levels of appetite-regulating hormones. CSD mice exhibited a 
marked increase in food intake: mean daily weight of pellet eaten was calculated for the 5-day 
blocks, pre-CSD/CON -4 to 0, CSD/CON 1-5, 6-10, 11-15. There was a Group x Day-block interaction 
(F(3,60)=13.95, p<0.0005, partial 2=0.54 Fig. 4A); pre-CSD/CON food intake was similar in CON and 
CSD mice, and CSD mice consumed more pellet than did CON mice at days 1-5, 6-10 and 11-15. For 
body weight, there was no effect of Group (p≥0.61, Fig. 4B), and a main effect of Day-block 
(F(3,60)=21.83, p<0.0005, partial 2=0.52, Fig. 4B) due to a general increase in BW over time. The 
increase in food intake in CSD mice co-occurred with a decrease in plasma levels of the appetite-
suppressant hormone leptin in samples collected on day 16 (CON: 5.242.26 ng/ml, CSD: 2.120.93 
ng/ml, t(21)=4.77, p<0.0002, d=1.95). There was no overall effect of CSD on plasma levels of the 
appetite-enhancing hormone ghrelin in the same mice (CON: 75.9028.42 pg/ml, CSD: 107.8070.24 
pg/ml, p=0.19). These findings demonstrated the important need to control the BW and pellet 
allocation for each mouse individually and on a daily basis, in order to maintain all mice at the same 
BW relative to baseline, and therefore in as homeostatic state as possible, for operant testing. 
     FIGURE 4 ABOUT HERE 
 
CSD and agomelatine effects in the progressive ratio schedule test 
In Study B, conducted with naive mice, with respect to baseline BW and pellet intake, mice (N=22) 
that were later allocated to CON weighed 28.21.62 g (=100% baseline BW) and consumed 3.80.4 g 
pellet/day, and mice (N=22) that were later allocated to CSD weighed 28.71.6 g and consumed 
3.80.5 g pellet/day. During the 15-day CSD/CON period, CON mice were given 3.10.5 g food 
pellet/day to maintain 100% baseline BW (actual values: 101.42.2%), whereas CSD mice needed to 
be given 4.70.7 g food pellet/day to maintain 100% baseline BW (actual values: 101.51.5%). 
Therefore, as observed in the ad libitum food intake experiment (Fig. 4), CSD mice required more 
food to maintain body weight. 
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 At CSD/CON day 8, which was prior to commencement of AGO administration (day 10, Fig. 1), 
mice were given a PRS test. At this stage there was no effect of CSD on the main measures of total 
number of operant responses (CON: 273236, CSD: 281177, p=0.91), reinforcements attained 
(CON: 27.411.8, CSD: 28.510.0, p=0.72), and final ratio attained (CON: 16.47.1, CSD: 17.45.8, 
p=0.63). However, the number of responses at the feeder was decreased in CSD mice (CON: 16488, 
CSD: 11068, t(42)=2.33 p<0.03, d=0.71), suggesting decreased reward anticipation. Within CON and 
CSD groups, the total number of PRS responses was used to counter-balance allocation of mice to 
AGO and VEH groups. 
 At CSD/CON day 15, which was day 6 of AGO administration, a further PRS test was 
conducted. At this stage, there was a consistent effect of CSD on PRS test behaviour. Thus, for total 
number of operant responses there was a main effect of Stress group (F(1,40)=11.44, p<0.002, partial 
2=0.22, Fig 5A) with CSD mice making less responses. CSD mice also attained fewer reinforcements 
(p<0.001, partial 2=0.24, Fig 5B) and a lower final ratio (p<0.001, partial 2=0.24, Fig. 5C) relative to 
CON mice. The number of responses at the feeder was also lower in CSD mice (CON: 15268, CSD: 
6943, p<0.0005, partial 2=0.24), suggesting decreased reward anticipation. With the exception of 
three CSD-VEH mice which reached break point, all mice continued responding to the end of the 40-
min PRS session. There was no Stress x Drug interaction or main effect of Drug for any PRS measure. 
However, as is evident in each data set in Figure 5, in CSD mice specifically there was an increase in 
the mean scores in mice receiving AGO; in t-tests, the final ratio attained in CSD-AGO versus CSD-VEH 
mice tended to increase without reaching statistical significance (p=0.07, d=0.81, Fig. 5C). There was 
no effect of AGO on the amount of food that needed to be given to maintain mice at 100% baseline 
BW, in either CSD or CON mice. 
     FIGURE 5 ABOUT HERE 
 
CSD and agomelatine effects in the reversal learning tests 
The same mice were then reduced to 95% baseline BW (CON: 96.22.2%, CSD: 973.3%, p=0.37) and 
studied in terms of CSD and AGO effects on reversal learning. At day 19, 4 days after the end of CSD 
and day 10 of AGO administration, mice were tested in the simple reversal learning test (Figure 6). 
There were main effects of Stress group, consistent with impaired test performance in CSD mice, for: 
number of reinforcements obtained (CON: 480, CSD: 4013, p<0.007, partial 2=0.17), probability 
of reward-stay responding (p<0.0005, partial 2=0.34, Fig. 6A), reversals completed (p<0.0005, partial 
2=0.27, Fig. 6B), trials per reversal (p<0.003, partial 2=0.19, Fig. 6D), average latency to collect 
reward (p<0.006, partial 2=0.17, Fig. 6E) and session duration (p<0.02, partial 2=0.15, Fig. 6F). 
There was no effect of CSD on perseverations per reversal (p=0.27, Fig. 6C). There was no Stress X 
Drug interaction or main effect of Drug for any SRL measure. 
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     FIGURE 6 ABOUT HERE 
 
 At day 22, mice were tested in the complex reversal learning test (Figure 7). There were main 
effects of Stress group, consistent with impaired test performance in CSD mice, for: number of 
reinforcements obtained (CON: 601, CSD: 5211, p<0.002, partial 2=0.21), probability of reward-
stay responding (p<0.004, partial 2=0.19, Fig. 7A), reversals completed (p<0.001, partial 2=0.23, Fig. 
7B), trials per reversal (p<0.03, partial 2=0.12, Fig. 7D), average latency to collect reward (p<0.04, 
partial 2=0.10) and session duration (p<0.0005, partial 2=0.34, Fig. 7F). Negative feedback 
sensitivity was actually reduced in CSD mice relative to CON mice (p<0.02, partial 2=0.14, Fig. 7E). In 
addition to the CSD effect on reversals completed, there was also a borderline non-significant effect 
of Drug (p<0.08, partial 2=0.07, Fig. 7B); in Stress group-specific t-tests, CSD-AGO mice completed 
more reversals than did CSD-VEH mice (p<0.03, d=0.93, Fig. 7B). For perseverations per reversal, 
there was a Stress x Drug interaction (p<0.03, partial 2=0.12, Fig. 7C), and post hoc tests identified 
that CSD-AGO mice perseverated more than each of the other three groups.  
     FIGURE 7 ABOUT HERE 
  
3.4. Study C: Effects of CSD and repeated agomelatine on reward motivation and circadian rhythm 
in the home cage  
In the first IntelliCage study, conducted with naive mice (Fig. 1C1), saccharin- and water-directed 
visits, nosepokes and licks, were compared in CSD and CON mice (Figure 8 and Table S1). Baseline 
(days -4 to 0) behaviour was similar in mice allocated at random to CON and CSD groups (Fig. 8A-D, 
Table S1); as expected (e.g. (Cathomas et al., 2015a)), under baseline conditions and primarily during 
the dark phase, mice had a moderate preference for the saccharin corner versus water corner in 
terms of visits and nosepokes, and a marked preference for saccharin over water in terms of licks. In 
mixed-factorial ANOVA, in cases of significant interaction of Stress x Day x Time and/or Stress x Day 
and/or Stress x Time, a posteriori Stress x Time analysis was conducted for each day-block separately. 
For saccharin visits (Stress x Day x Time p<0.03, partial 2=0.12), CSD mice made less saccharin visits 
than CON mice during the dark phase at day-blocks CSD 1-5, 6-10 and 11-15 (p<0.01-0.05, Table S1). 
A similar CSD effect pertained for water visits (Stress x Day x Time p<0.0005, partial 2=0.21), with 
CSD mice making less visits than CON mice during the dark phase at day blocks CSD 1-5, 6-10 and 
11.15 (p<0.01-0.05, Table S1), and also CSD mice making more water visits than CON mice during the 
light phase at day-blocks CSD 6-10 and 11-15 (p<0.01-0.05, Table S1). Together, these data suggest a 
general decrease in goal-directed dark-phase activity in CSD mice. For saccharin nosepokes (Stress x 
Day x Time p<0.02, partial 2=0.13), CSD mice made less saccharin nosepokes than CON mice during 
the dark phase at day-blocks CSD 1-5, 6-10 and 11-15 (p<0.05, Fig. 8A, Table S1). A similar CSD effect 
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pertained for water nosepokes (Stress x Time p<0.03, partial 2=0.31), with CSD mice making less 
nosepokes than CON mice during the dark phase at day-blocks 1-5, 6-10 and 11-15 (p<0.05-0.01, Fig. 
8B, Table S1), again consistent with a general decrease in appetitive behaviour. For saccharin licking 
(Stress x Day x Time p<0.05, partial 2=0.11, Fig. 8C, Table S1), CSD mice made less saccharin licks 
than CON mice during the dark phase at day-block CSD 11-15, consistent with decreased interest in 
saccharin by this stage (p<0.05, Fig. 8C, Table S1). For water licks (Stress x Day x Time p<0.0005, 
partial 2=0.19, Fig. 8D, Table S1), CSD mice made more licks than CON mice during the light phase at 
day-blocks CSD 1-5 and 6-10 (p<0.001-0.01, Fig. 8D, Table S1), possibly reflecting increased activity 
including feeding during this period.  
 In the second IntelliCage study, conducted with naive mice (Fig. 1C2), in which CSD-AGO and 
CSD-VEH mice were compared (Figure 9A-D and Table S2), the saccharin- and water-directed 
behavioural profiles of these mice were similar to those of the CSD mice in the first experiment. This 
was indicated by the main effect of Day-block in the Drug x Day-block x Time-block ANOVA, 
attributable to a decrease in behaviour relative to baseline (days -4 to 0) in at least one CSD/post-CSD 
day-block, for dark-phase saccharin visits, dark-phase saccharin nosepokes (see Fig. 9A) and dark-
phase saccharin licks (see Fig. 9C). Furthermore, light-phase water licks were increased in CSD/post-
CSD day-blocks relative to baseline (see Fig. 9D). There were no significant effects involving Drug for 
any behavioural measure in these CSD mice. 
     FIGURE 8 ABOUT HERE 
     FIGURE 9 ABOUT HERE 
 
4. Discussion      
In the present study we could demonstrate that exposure of mice to chronic psychosocial stress 
leads in discrete operant tests to: decreased motivation to exert physical effort for gustatory 
reinforcement, and to decreases in both response accuracy and negative feedback sensitivity when 
cognitive effort is required to obtain gustatory reinforcement. Furthermore, in the home cage, 
appetitive and to a lesser extent consummatory responding to gustatory reward were decreased. At 
a pharmacological dose, the antidepressant agomelatine was effective in reducing the stress-induced 
deficit in complex reversals completed, and this was associated with an increase in perseveration 
which was adaptive under the test conditions. These findings add considerably to the evidence that 
mouse models relevant to stress-induced disruption of the motivation and cognitive flexibility to 
interact with rewarding stimuli, core and common psychopathology domains in depression, can be 
developed. Furthermore, the partial reversal of these deficits by the antidepressant AGO provides 
some evidence for the predictive validity of the model. 
 
17 
 
4.1. Positive agomelatine and 5-HT2C-antagonist effects on complex reversal learning  
 In the complex reversal learning (CRL) test, an acute dose of AGO at 25 mg/kg or of a 5-HT2C 
antagonist, administered orally 1-2 hours prior to testing, led to an increase in the number of 
reversals completed by otherwise non-manipulated mice; no effect was observed with AGO at 10 
mg/kg or melatonin in the same experiment. Although neither measure responded significantly, AGO 
(25 mg/kg) and S32006 did result in a mean increase in reward-stay probability and a mean decrease 
in negative feedback sensitivity (NFS), suggesting that these two effects contribute additively to the 
significant drug effects on reversals completed. In a previous study, a low, acute dose of the 
antidepressant escitalopram increased reward-stay, decreased NFS and increased reversals 
completed in mice in this CRL test (Ineichen et al., 2012). In healthy humans, 3-day AGO 
administration led to increased reward-stay probability in probabilistic reversal learning tests 
compared with vehicle and escitalopram (Salvador et al., 2014). In a simple reversal learning test in 
rat, another 5-HT2C antagonist, SB 242084, also improved reversal learning (Boulougouris et al., 
2008). 5-HT2C receptors are expressed in a number of forebrain regions important in the regulation of 
operant behaviour, including frontal cortex, amygdala, hippocampus, and dorsal and ventral 
striatum. 5-HT2C antagonism disinhibits dopamine (DA) release into frontal cortex specifically (Di 
Giovanni et al., 2006; Millan et al., 2003), as demonstrated after AGO administration in rats (Millan et 
al., 2003). 5-HT2C receptors are also expressed in monoamine cell-body regions, including ventral 
tegmental area (VTA) for DA and locus coeruleus for noradrenaline (NA) (Pompeiano et al., 1994; 
Racagni et al., 2011). In VTA, 5-HT2C receptors are expressed by GABA interneurons that project onto 
DA neurons (Eberle-Wang et al., 1997). AGO, acute and chronic, increases the number of 
spontaneously active VTA DA neurons and the bursting activity of VTA dopaminergic neurons (Chenu 
et al., 2013). Nonetheless, 5-HT2C antagonism does not disinhibit DA release in nucleus accumbens or 
dorsal striatum (Millan et al., 2003).   
 
4.2. CSD-induced amotivation and cognitive deficits for operant-reward 
 Chronic social defeat resulted in increased food intake, as described previously (Kumar et al., 
2013). This occurred in the absence of an effect on body weight, consistent with CSD inducing an 
increase in energy expenditure. In blood samples collected on day 16 from these same mice, there 
was a decrease in plasma leptin levels, as reported previously for CSD (Kumar et al., 2013). Leptin is 
an adipokine released from fat into the circulation. It is transported across the blood-brain-barrier 
where it acts to suppress feeding. It acts at homeostatic areas (e.g. brainstem, hypothalamus) as well 
as areas involved in reward-motivation such as VTA. The reduction in plasma leptin observed in CSD 
mice relative to CON mice under free-feeding conditions would be expected to contribute to their 
increased feeding by disinhibition. There was no consistent effect of CSD on the active form of 
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ghrelin, which acts to promote feeding and has been reported to be increased by CSD and to underlie 
the increased feeding by CSD mice that, in contrast to the present study, exhibited increased body 
weight (Patterson et al., 2013). These findings confirmed the importance of providing CSD and CON 
mice with the group- and individual-specific feeding regimens that were required for maintaining the 
required level of baseline body weight, in order to ensure that all mice were in as similar state as 
possible for operant testing. 
 Chronic social defeat was without effect on reward motivation in the progressive ratio 
schedule (PRS) test at CSD day 8, but had resulted in decreased reward motivation under these 
effortful conditions relative to CON mice, as indicated by the inter-related reductions in number of 
responses and rewards and final ratio attained, by the final day, 15, of CSD. In human depression, 
patients do not differ from healthy controls in their reports of the intensity and pleasantness of 
sucrose, indicating that hedonic reactivity to reward consumption is intact (Dichter et al., 2010). 
However, using monetary reward, depressed patients exhibit reduced motivation to expend effort to 
obtain reward (Treadway et al., 2012). In the same mice, testing in the simple reversal learning (SRL) 
test at day 19 and the CRL test at day 22 identified further disruption of reward processing in mice 
that had experienced CSD. Thus, in the SRL test CSD mice exhibited reduced reward-stay accuracy, 
completed less reversals, and required more trials per reversal, relative to CON mice. That these 
effects co-occurred in CSD mice with reduced reward motivation – despite testing being conducted 
at 95% baseline body weight - was indicated by their increased latency to collect the sucrose-pellet 
after a correct response. The CSD-induced deficits in the SRL test also pertained in the CRL test at day 
22. That performance in terms of reward-stay accuracy and reversals completed was reduced in both 
CON and CSD mice in the CRL relative to the SRL test, confirms the increased cognitive demands of 
the former test. In addition to reduced motivation, reduced ability to accurately monitor the correct 
operant stimulus (i.e. nose poke aperture) under cognitively effortful conditions and reduced reward 
expectancy, are two further potential deficits that could account for the CSD effects observed in 
these tests. In the CRL test specifically, negative feedback sensitivity was assessed, and interestingly 
CSD actually caused a decrease in NFS. Non-manipulated mice, relative to healthy humans, exhibit 
high NFS in this type of test: we have interpreted this as evidence that mice are indeed able to 
monitor reward expectancy in the CRL test, experience the withholding of an expected 
reinforcement as aversive and, in contrast to healthy humans, cannot routinely inhibit switching to 
the opposite operant stimulus on the next trial (Ineichen et al., 2012). Against this background, the 
reduced NFS in CSD mice could indicate reduced cognitive ability to monitor reward expectancy, 
reduced negative emotionality when an expected reinforcement is withheld, or reduced reward 
expectancy. In the human PRL test, depressed patients exhibit intact reward-stay accuracy and 
reversals completed in combination with increased NFS, relative to healthy controls (Taylor Tavares 
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et al., 2008). Therefore, the constellation of CSD effects in the mouse CRL test is clearly not a 
recapitulation of the effects of depression in the human PRL test. Despite this, the mouse CSD-CRL 
test model comprises stress-induced deficits in reward-directed behaviour under cognitively 
demanding conditions, and this is certainly of high relevance to the major depression 
psychopathology of reduced motivation and interest in daily activities.  
 Evidence that CSD also causes continuous reduction in motivation to engage in appetitive 
behaviour in a home cage setting, complementary to that obtained in the discrete testing conditions 
of the PRS test, was provided by the IntelliCage experiment. CSD mice developed reduced goal-
directed behaviour (visits, nosepokes) for saccharin and water during the active period of their 
circadian cycle from the first days of CSD. Towards the end of CSD they had also developed reduced 
consumption (licks) of saccharin during the active period. During the inactive period, the water 
consumption of CSD mice increased, possibly indicating that they were more active than CON mice 
during this period and eating more food, which stimulates drinking. 
 Using a different CSD protocol (10 days) to that of the present study, in some studies CSD 
mice have been divided into susceptible and resilient sub-groups based on a social interaction test in 
which social avoidance of a mouse of the strain (CD-1) used for CSD is measured (e.g. Krishnan et al., 
2007). Susceptible mice are defined as those that exhibit increased avoidance of the CD-1 mouse 
compared to controls, and resilient mice as those that exhibit avoidance overlapping with that shown 
by control mice. By categorising mice in this way it has been possible to demonstrate behavioural 
effects of CSD in some other tests specific to the susceptible group e.g. decreased sucrose preference 
(Krishnan et al., 2007). Using our 15-day CSD protocol and treating CSD mice as one group we have 
obtained significant CSD effects in terms of increased fear conditioning, learned helplessness and 
fatigue (Azzinnari et al., 2014; Fuertig et al., 2016), and now in the present study in terms of reward-
directed operant behaviour in motivation and cognitive tests. This “inclusive” experimental design 
has been used extensively with other stressors, such as chronic unpredictable mild stress (e.g. Tye et 
al., 2013; Willner, 1997). 
 
4.3. Partial reversal of CSD amotivation and cognitive effects with repeated agomelatine 
 Agomelatine, using the dose of 25 mg/kg at which acute administration led to increased 
reversals completed in the CRL test in non-manipulated mice, exerted some normalising effects on 
operant behaviour when administered repeatedly in CSD mice. Firstly, there was a tendency to 
increase motivation for reward in the PRS test conducted after 6 days of repeated AGO, in CSD mice. 
A similar reduction in motivation in the PRS test to that observed in CSD mice is induced by 6-
hydroxydopamine depletion of DA in the nucleus accumbens (Bergamini et al., in press ). 
Extrapolating to the current findings, this suggests that AGO effects on the VTA-DA pathway 
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mediated via it 5-HT2C antagonist properties (Chenu et al., 2013) could have contributed to the 
increased motivation in CSD-AGO mice. Whilst there were no effects of 10 days of AGO in the SRL 
test, 13 days of AGO resulted in an increase in reversals completed in the more demanding CRL test 
in CSD mice specifically. Furthermore, this co-occurred with an increase in the average number of 
perseverations per reversal in CSD-AGO mice compared with each of the other groups. In the CRL 
test, where there are non-rewarded correct responses (NR-CRs) that could be interpreted - 
incorrectly - as initiation of reversal, it is actually adaptive to be perseverative because this allows for 
differentiation between non-rewarded correct response trials and onset of reversal trials. Two 
perseverative responses per NR-CR/reversal are sufficient in this respect: CSD-AGO mice made a 
mean of 2-3 perseverations per reversal and each of the other groups made a mean of 1-2 
perseverations per reversal. This co-occurred with CSD-AGO mice also exhibiting the lowest mean 
NFS score of all groups. Therefore, repeated AGO produced increased perseveration specifically in 
CSD mice and specifically in the CRL test where, in contrast to the SRL test, some perseveration is 
adaptive. This might represent a first indicator of normalisation of reward expectancy and motivation 
in CSD mice, due to repeated administration of AGO. With regards to underlying mechanisms, the 
prefrontal cortex and nucleus accumbens are major regions in the regulation of perseveration (Clarke 
et al., 2004; Cools et al., 2007). In rat, the 5-HT2C antagonist SB 242084 decreased perseveration in a 
reversal learning test (Boulougouris et al., 2008), suggesting that the current increase in 
perseveration in AGO-treated CSD mice might not be directly related to 5-HT2C antagonism. Also in 
rat, infusion of the D2 receptor antagonist eticlopride into the PFC increased perseveration (Floresco 
et al., 2006). In Parkinson’s disease patients, ι-DOPA increases perseveration in a probabilistic 
reversal learning test, associated with disrupted activity related to excessive DA signalling in the 
nucleus accumbens (Cools et al., 2001; Cools et al., 2007). 5-HT2C receptor antagonists and AGO 
increase DA release into frontal cortex (Di Giovanni et al., 2006; Millan et al., 2003) and AGO 
increases bursting activity of VTA dopaminergic neurons (Chenu et al., 2013). Therefore, the AGO-
related increase in perseveration specific to CSD mice could reflect increased sensitivity to up-
regulated DA signalling following a prolonged period of low DA tone in the mesocorticolimbic 
pathway. It has been demonstrated that chronic stress leads to decreased activity of VTA neurons in 
mice (Tye et al., 2013). Despite the evidence that 5-HT2C antagonism might stimulate appetite for 
food (Voigt and Fink, 2015), the absence of AGO effects on operant behaviour in CON mice indicates 
the absence of any such confounding effect in the present study. 
 There were no effects of AGO on the CSD-induced deficits in appetitive behaviour and shifts 
in circadian activity in IntelliCage. This indicates that the observed effects of AGO were specific to 
reward processing occurring under demanding test conditions, namely high physical effort in the PRS 
test or high cognitive effort in the CRL test.  Reinstatement of typical levels of maintenance and 
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reward-directed behaviour under low-effort/cognition conditions might require a longer duration of 
AGO exposure. 
 
4.4. Conclusion 
 in this study, psychosocial defeat stress has been demonstrated to lead to behavioural 
changes consistent with decreases in reward motivation, stimulus-reward monitoring and reward 
expectancy. Furthermore, CSD increased activity during the inactive phase of the circadian cycle. 
Given that these behavioural processes are directly relevant to the RDoC domain of positive valence 
systems, and similar deficits have been reported in depressed patients, the model established here 
demonstrates aetiological and face validity. Partial reversal of these deficits by the antidepressant 
agomelatine provides some evidence for the model’s predictive validity. Future studies with the 
model will investigate the neurobiological underpinnings of the stress-induced deficits in reward 
processing.  
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Figure legends 
Figure 1. Experimental designs. (A) Study A: Latin square design to study effects of acute 
agomelatine, melatonin and S 32006, a 5-HT2C receptor, antagonist on behaviour in a complex 
reversal learning test in otherwise non-manipulated mice. (B) Study B: Effects of chronic social defeat 
versus control handling and AGO versus vehicle on behaviour in a progressive ratio schedule test and 
simple and complex reversal learning tests. (C) Study C: Experiment 1, effects of CSD versus CON 
handling on appetitive and consummatory behaviour towards water and saccharin solution during 
the dark- and light-phases of the circadian cycle. Experiment 2, effects of AGO versus vehicle on 
these same measures in CSD mice. Baseline BW/b-BW: baseline body weight; FI: Food intake; SRL: 
simple reversal learning test; CRL: complex reversal learning test; D: acute drug; CSD: chronic social 
defeat; CON: control handling; PRS: progressive ratio schedule test; AGO: agomelatine; VEH: vehicle. 
 
Figure 2. Agomelatine concentrations in (A) trunk blood plasma and (B) whole brain tissue in the 
same naive mice following oral administration of agomelatine at 10 or 25 mg/kg at the end of the 
light phase and sample collection after 1 or 3 hours. N=6-7 mice per dose and time point. In (A) and 
(B), there was a Drug dose x Time interaction in ANOVA, and dose/time points with different letters 
(a vs b) were different (p<0.005) according to pairwise Bonferroni testing. Note the different Y-axis 
scales used in (A) and (B).  
 
Figure 3. Compound- and dose-dependent effects of vehicle, agomelatine (AGO, 10 and 25 mg/kg), 
melatonin (MT, 10 mg/kg) and S 32006, a 5-HT2C antagonist (5-HT2C ANT, 2.5 mg/kg) on behaviour in 
the complex reversal learning (CRL) test. The test was conducted 1-2 hours after p.o. compound had 
been administered at the end of the light phase. A latin square design for the order of 
compound/dose testing was used. Twenty four mice were studied, and each mouse obtained the 
maximum 60 reinforcements in each test session. A) Probability of reward-stay responding. B) 
Negative feedback sensitivity (NFS) with respect to switching stimulus after a non-rewarded correct 
response. C) Number of reversals. Values are mean  SD. * p<0.05 for post hoc Bonferroni testing 
conducted after a main effect of Drug.  
 
Figure 4. Effects of chronic social defeat on mouse food intake and body weight. A) Mean food intake 
per 5-day block. B) Mean body weight per 5-day block. The weights of food given and remaining were 
measured each day at 16:00 h. Values are mean +/- SD. In A) *** p<0.001 for Bonferroni tests 
conducted for Stress group in specific Day-blocks following a Stress group x Day-block interaction in 
ANOVA. In B) day-blocks with different letters (a vs b) p<0.05 or less for Bonferroni tests following 
main effect of Day-block. 
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Figure 5. Effects of chronic social defeat and repeated agomelatine (25 mg/kg p.o.) on mouse 
behaviour in the progressive ratio schedule test, at day 15 (final day) of CSD and after 6 days of AGO. 
The test was conducted 1-2 hours after AGO/VEH had been administered at the end of the light 
phase. Eleven mice per group were tested, counter-balanced with respect to baseline behaviour in 
this test. (A) Total number of nosepoke responses. (B) Number of reinforcements attained. (C) Final 
ratio attained. In A-C, p values are for the main effect of Stress group in a Stress group x Drug dose 
ANOVA. In C, in a Stress group-specific t-test, there was a borderline non-significant increase in the 
final ratio attained in CSD-AGO versus CSD-VEH mice. 
 
Figure 6. Effects of chronic social defeat and repeated agomelatine (25 mg/kg p.o.) on mouse 
behaviour in the simple reversal learning test, at 4 days after completion of CSD and after 10 days of 
AGO. The test was conducted 1-2 hours after AGO/VEH had been administered at the end of the light 
phase. Eleven mice per group were tested. (A) Probability of reward-stay responding. (B) Number of 
reversals completed. (C) Perseverations per reversal. (D) Trials per reversal. (E) Latency to collect 
reward from feeder. (F) Session duration. p values are for the main effect of Stress group in a Stress 
group x Drug dose ANOVA.        
 
Figure 7. Effects of chronic social defeat and repeated agomelatine (25 mg/kg p.o.) on mouse 
behaviour in the complex reversal learning test, at 7 days after completion of CSD and after 13 days 
of AGO. The test was conducted 1-2 hours after AGO/VEHhad been administered at the end of the 
light phase. Eleven mice per group were tested. (A) Probability of reward-stay responding. (B) 
Number of reversals completed. (C) Perseverations per reversal. (D) Trials per reversal. (E) Negative 
feedback sensitivity to non-reward of a correct response. (F) Session duration. In A, D-F, p values are 
for the main effect of Stress group in Stress group x Drug dose ANOVA. In B, there was a main effect 
of Stress group and borderline main effect of Drug group; Stress group-specific t-tests identified 
increased reversals due to AGO in CSD mice specifically (p<0.03). In C, there was a Stress group x 
Drug dose interaction, and p values are for Bonferroni pairwise tests (p<0.01). 
 
Figure 8. Effects of chronic social defeat on mouse behaviour relative to saccharin and water, as 
measured continuously in IntelliCage. A) Saccharin nosepokes. B) Water nosepokes. C) Saccharin 
licks. D) Water licks. Seven CSD and 11 CON mice were studied; one mouse from each group had to 
be excluded because of technical problems. Each data point is the overall mean of 5-day-mean values 
per mouse, obtained in 5 days prior to CSD/CON, CSD/CON days 1-5, 6-10 and 11-15, for each given 
4-h period. Time periods were 20:00-00:00 and 00:00-04:00 during the light/inactive phase, 04:00-
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08:00 spanning the light-dark transition, and 08:00-12:00 and 12:00-16:00 during the dark/active 
phase. Daily CSD/CON procedures were carried out at 16:00-17:00 and the data obtained in the 3-4 h 
period thereafter were excluded from the analysis, as were the data obtained at 04:00-08:00. 
Following Stress group x Time period interaction, * p<0.05, ** p<0.01, *** p<0.001 are for time-
period specific Bonferroni tests of CSD versus CON mice. For additional data see Table S1.      
 
Figure 9. Absence of effects of repeated agomelatine (25 mg/kg p.o.) in mice exposed to chronic 
social defeat on behaviour relative to saccharin and water, as measured continuously in IntelliCage. 
A) Saccharin nosepokes. B) Water nosepokes. C) Saccharin licks. D) Water licks. Eight CSD and 8 CON 
mice were studied. Each data point is the overall mean of 5-day-mean values per mouse, obtained in 
5 days prior to CSD, on CSD days 1-5 without AGO/VEH, on CSD days 6-10 with AGO/VEH 
administration starting on day 7, on CSD days 11-15 with AGO/VEH, and on post-CSD days 16-20 with 
AGO/VEH, for each given 4-h period. Time periods were 20:00-00:00 and 00:00-04:00 during the 
light/inactive phase, 04:00-08:00 spanning the light-dark transition, and 08:00-12:00 and 12:00-16:00 
during the dark/active phase. Daily CSD was carried out at 16:00-17:00 and the data obtained in the 
3-4 h period thereafter were excluded from the analysis, as were the data obtained at 04:00-08:00. 
AGO/VEH were administered at 06:00-07:00. In Drug group x Time period interactions, there were no 
significant main or interaction effects that included Drug dose. For additional data see Table S2. 
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Table S1. Summary of IntelliCage behaviour in Experiment C1, according to reward, stress group, 
day-block and time-period 
              
 Light Phase (20-00 h, 00-04 h) Dark Phase (08-12 h, 12-16 h) 
Reward/Measure/Day-block CON/CSD CON/CSD 
Saccharin Visits -4 to 0 2.22±0.94/1.80±1.00 11.60±3.88/9.20±2.43 
Saccharin Visits 1-5 1.91±0.87/4.97±1.13 11.42±6.70/5.14±2.81* 
Saccharin Visits 6-10 2.20±1.68/3.83±1.68 10.58±5.45/5.40±2.85* 
Saccharin Visits 11-15 1.75±0.81/4.07±2.39 10.29±3.41/4.99±3.27** 
   
Saccharin Nosepokes -4 to 0 4.00±2.55/2.74±1.66 23±11.90/18.71±6.73 
Saccharin Nosepokes 1-5 3.02±1.28/8.74±3.07 22.71±12.61/8.31±4.89* 
Saccharin Nosepokes 6-10 3.95±4.40/6.74±2.34 23.04±17.34/8.34±5.81* 
Saccharin Nosepokes 11-15 2.76±1.39/6.36±3.36 20.80±10.07/9.04±6.61* 
   
Saccharin Licks -4 to 0 89.16±55.43/72.69±75.55 449.55±239.39/493.86±136.51 
Saccharin Licks 1-5 77.60±63.48/261.03±141.84 438.87±241.30/322.91±259.64 
Saccharin Licks 6-10 73.02±53.62/206.26±85.20 401.15±226.82/260.66±254.38 
Saccharin Licks 11-15 54.65±37.93/153.14±118.60 454.47±193.53/210.41±209.70* 
   
Water Visits -4 to 0 0.84±0.44/0.97±0.65 6.27±4.22/4.75±2.62 
Water Visits 1-5 1.07±0.75/1.86±1.16 7.33±4.95/1.03±0.61* 
Water Visits 6-10 1.65±1.19/6.57±3.46** 6.39±5.05/1.69±1.29** 
Water Visits 11-15 1.13±1.06/4.75±3.70* 7.83±4.11/2.39±2.05** 
   
Water Nosepokes -4 to 0 1.13±1.22/1.60±1.60 12.75±18.38/10.74±10.88 
Water Nosepokes 1-5 1.51±1.28/2.03±1.08 11.27±11.77/1.03±1.56** 
Water Nosepokes 6-10 1.38±1.16/4.89±3.55 13.78±18.66/1.06±0.98* 
Water Nosepokes 11-15 1.24±1.06/4.25±2.94 15.45±16.40/3.09±2.71* 
   
Water Licks -4 to 0 2.84±3.94/3.43±6.31 20.60±30.60/35.34±67.25 
Water Licks 1-5 10.20±14.14/114.23±120.18** 36.15±63.86/8.23±9.38 
Water Licks 6-10 8.04±11.53/178.74±193.32*** 16.85±32.51/23.09±44.37 
Water Licks 11-15 5.46±7.39/74.18±107.45 38.95±70.58/22.77±30.57 
   
Preference Visits -4 to 0 73.39±6.47/65.20±17.70 66.81±9.04/67.94±11.96 
Preference Visits 1-5 68.96±14.08/74.09±11.20 62.71±9.25/81.66±9.78** 
Preference Visits 6-10 69.27±9.89/58.84±8.63* 67.13±8.94/79.64±11.39* 
Preference Visits 11-15 70.95±17.40/59.42±16.45 59.42±10.86/70.58±17.10 
   
Preference Nosepokes -4 to 0 80.61±9.61/67.03±22.96 72.14±16.14/70.02±15.43 
Preference Nosepokes 1-5 71.23±14.89/81.60±9.55 71.38±10.34/88.10±11.34* 
Preference Nosepokes 6-10 71.52±18.67/62.51±13.15 71.26±16.39/87.88±10.21 
Preference Nosepokes 11-15 73.86±22.14/58.96±23.84 66.33±16.60/74.89±17.83 
   
Preference Licks -4 to 0 97.60±3.31/91.46±18.28 96.24±3.67/93.40±12.56 
Preference Licks 1-5 92.89±8.48/75.55±17.50* 93.88±8.80/93.94±7.40 
Preference Licks 6-10 91.76±14.15/77.46±15.67 96.22±8.03/96.01±6.17 
Preference Licks 11-15 87.53±23.70/70.17±27.79 92.69±11.53/87.10±16.35 
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Table S2. Summary of IntelliCage behaviour in Experiment C2, according to reward, drug group, 
day-block and time-period 
              
 Light Phase (20-00 h, 00-04 h) Dark Phase (08-12 h, 12-16 h) 
Reward/Measure/Day-block VEH/AGO VEH/AGO 
Saccharin Visits -4 to 0 1.85±1.11/2.45±1.23 14.30±6.32/12.28±3.93 
Saccharin Visits 1-5 4.23±1.48/3.45±1.47 11.03±3.53/9.43±2.71 
Saccharin Visits 6-10 2.88±1.23/3.10±1.89 8.23±4.66/12.45±6.35 
Saccharin Visits 11-15 1.58±0.94/2.50±0.87 10.93±4.30/10.78±3.08 
Saccharin Visits 16-20 1.63±0.74/2.35±1.44 11.28±3.12/8.69±2.15 
   
Saccharin Nosepokes -4 to 0 2.83±1.59/3.78±2.12 27.45±21.47/19.73±6.62 
Saccharin Nosepokes 1-5 7.65±3.60/5.60±2.35 19.15±11.10/14.80±4.32 
Saccharin Nosepokes 6-10 6.25±3.67/5.88±3.93 14.18±7.59/17.95±5.45 
Saccharin Nosepokes 11-15 3.05±1.65/4.18±1.41 15.88±9.59/16.25±5.43 
Saccharin Nosepokes 16-20 2.67±1.60/4.16±2.78 11.43±13.7114.08±4.87 
   
Saccharin Licks -4 to 0 60.70±58.53/82.95±46.83 557.63±149.45/723.08±249.23 
Saccharin Licks 1-5 225.93±163.18/135.23±34.58 666.23±280.45/448.53±237.54 
Saccharin Licks 6-10 170.58±120.48/115.08±67.63 532.45±316.55/428.93±198.57 
Saccharin Licks 11-15 62.43±44.38/120.13±74.29 379.25±178.36/475.83±200.32 
Saccharin Licks 16-20 64.43±50.11/110.17±61.19 515.45±220.31/334.64±120.43 
   
Water Visits -4 to 0 0.68±0.46/0.78±0.37 6.40±3.53/4.98±2.70 
Water Visits 1-5 1.08±0.59/1.58±1.27 3.48±1.76/3.83±2.01 
Water Visits 6-10 1.40±0.57/1.78±1.12 3.95±2.26/5.70±3.94 
Water Visits 11-15 0.85±0.48/1.05±0.62 6.50±3.99/5.35±3.59 
Water Visits 16-20 1.38±0.43/1.35±0.61 5.48±2.14/3.30±2.33 
   
Water Nosepokes -4 to 0 0.70±0.54/0.63±0.27 8.43±7.02/6.53±4.55 
Water Nosepokes 1-5 1.48±1.34/3.20±3.11 3.93±3.87/3.93±3.14 
Water Nosepokes 6-10 2.10±1.36/2.9±2.45 5.13±4.88/5.80±5.45 
Water Nosepokes 11-15 1.33±1.26/1.85±1.22 7.93±7.84/5.90±3.77 
Water Nosepokes 16-20 1.68±0.92/2.08±0.88 6.55±3.26/4.16±3.3.7 
   
Water Licks -4 to 0 0.08±0.20/0.80±1.44 3.45±5.37/4.68±10.06 
Water Licks 1-5 22.13±31.11/39.45±59.39 36.05±53.63/59.43±79.29 
Water Licks 6-10 35.73±35.02/45.16±86.44 81.78±131.70/80.75±176.67 
Water Licks 11-15 12.55±15.52/37.63±52.55 67.70±96.33/78.65±130.54 
Water Licks 16-20 12.53±14.98/33.61±42.62 27.68±50.65/62.73±111.84 
   
Preference Visits -4 to 0 73.22±15.32/78.09±9.62 69.16±10.86/73.20±10.11 
Preference Visits 1-5 80.37±8.49/71.44±16.03 76.14±9.15/71.17±13.85 
Preference Visits 6-10 66.69±8.13/64.97±13.66 66.75±14.22/69.34±17.49 
Preference Visits 11-15 67.29±14.83/72.18±10.75 64.06±9.19/69.65±11.39 
Preference Visits 16-20 52.40±14.96/65.34±20.03 67.15±9.47/75.02±12.52 
   
Preference Nosepokes -4 to 0 79.91±19.27/85.45±8.90 75.11±15.51/75.91±13.37 
Preference Nosepokes 1-5 85.25±8.29/69.91±23.54 84.81±8.62/80.32±14.00 
Preference Nosepokes 6-10 72.38±12.86/70.05±19.69 73.89±15.81/77.09±20.41 
Preference Nosepokes 11-15 75.63±15.30/71.88±13.19 68.59±14.20/75.27±11.85 
Preference Nosepokes 16-20 59.58±19.56/67.70±17.59 74.28±13.22/80.07±13.98 
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Preference Licks -4 to 0 99.46±1.42/98.59±2.90 99.32±1.23/99.04±2.01 
Preference Licks 1-5 91.74±10.22/85.41±18.89 94.42±6.73/89.31±17.10 
Preference Licks 6-10 86.29±11.62/83.69±27.40 83.45±20.18/87.94±25.78 
Preference Licks 11-15 85.95±13.64/84.04±19.60 85.57±15.87/88.72±15.83 
Preference Licks 16-20 88.28±9.08/81.37±22.13 93.84±10.05/89.29±19.07 
              
 
